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Introduction: Evidence has shown that utilization of antiosteoporotic medications does
not correspond with risk, and studies on other therapies have shown that adequacy of
pharmaceutical prescribing might vary between regions. Nevertheless, very few studies
have addressed the variability in osteoporotic drug consumption. We aimed to describe
variations in pharmaceutical utilization and spending on osteoporotic drugs between
Health Areas (HA) in Spain.
Methods: Population-based cross-sectional ecological study of expenditure and
utilization of the five therapeutic groups marketed for osteoporosis treatment in Spain
in 2009. Small area variation analysis (SAVA) methods were used. The units of analysis
were the 168 HA of 13 Spanish regions, including 7.2 million women aged 50 years and
older. The main outcomes were the defined daily dose (DDD) per 1000 inhabitants and
day (DDD/1000/Day) dispensed according to the pharmaceutical claims reimbursed,
and the expenditure on antiosteoporotics at retail price per woman ≥50 years old and
per year.
Results: The average osteoporosis drug consumption was 116.8 DDD/1000W/Day,
ranging from 78.5 to 158.7 DDD/1000W/Day between the HAs in the 5th
and 95th percentiles. Seventy-five percent of the antiosteoporotics consumed
was bisphosphonates, followed by raloxifene, strontium ranelate, calcitonins, and
parathyroid hormones including teriparatide. Regarding variability by therapeutic
groups, biphosphonates showed the lowest variation, while calcitonins and parathyroid
hormones showed the highest variation. The annual expenditure on antiosteoporotics
was €426.5 million, translating into an expenditure of €59.2 for each woman ≥50 years
old and varying between €38.1 and €83.3 between HAs in the 5th and 95th percentiles.
Biphosphonates, despite accounting for 79% of utilization, only represented 63% of
total expenditure, while parathyroid hormones with only 1.6% of utilization accounted
for 15% of the pharmaceutical spending.
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Conclusion: This study highlights a marked geographical variation in the prescription
of antiosteoporotics, being more pronounced in the case of costly drugs such as
parathyroid hormones. The differences in rates of prescribing explained almost all of
the variance in drug spending, suggesting that the difference in prescription volume
between territories, and not the price of the drugs, is the main source of variation in this
setting. Data on geographical variation of prescription can help guide policy proposals
for targeting areas with inadequate antiosteoporotic drug use.
Keywords: osteoporosis, geographical variation, pharmaceutical utilization, expenditure, medication, hip fracture
prevention
INTRODUCTION
Osteoporotic fractures, and among them hip fractures – the
more severe clinical manifestation of osteoporosis – account
for the majority of fracture-related health care expenditure
and mortality in men and women aged 50 years and over
(Johnell and Kanis, 2006; Ström et al., 2011). Although directing
prevention strategies at high-risk groups is a key component
of cost-effective policies seeking to lower the incidence and
impact of osteoporotic fractures, evidence has shown that
utilization of antiosteoporotic medications does not correspond
with risk, and the Spanish setting is a good example: whereas
Spain is one of the European (and worldwide) countries
with a lower incidence of osteoporotic fracture (Kanis et al.,
2012; Hernlund et al., 2013), antiosteoporotic medications
are among the most widely prescribed drugs in the Spanish
National Health System (sNHS). A report from 2010 analyzing
variability in the consumption of several therapeutic drugs in
15 developed countries (including the United States, Canada,
and some European countries) placed Spain as the country
with the highest utilization of antiosteoporotic drugs (Richards,
2010). Moreover, previous studies suggest that various countries
including Spain are seeing a massive use of osteoporotic
treatments in young women with a very low risk of fracture,
while there is a significant underuse in women (and men)
at a high risk of fracture, including those who have already
suffered a major osteoporotic fracture (de Felipe et al.,
2010; Sanfélix-Genovés et al., 2013b; Wang et al., 2013; Yu,
2017).
This might be due to the existence of considerable uncertainty
about how to quantify the risk, who should receive densitometry
testing, who should be treated, what treatment should be used,
and for how long (Bolland and Grey, 2010; Sanfélix-Genovés
et al., 2013a; Hurtado et al., 2014). Furthermore, and beyond
the evidence provided by clinical trials and the agreements
reached by expert consensus panels, treatment decisions and
the choice of a particular treatment may be influenced by
patient characteristics, physician, and organizational factors,
pharmaceutical promotion, and healthcare system characteristics
such as copayment, accessibility, or others (Eisenberg, 2002).
The lack of strong, coherent, and widely accepted guidance
for pharmacological treatment aimed at preventing fragility
fractures may result in a wide variation in the patterns of
drug use among neighboring populations with very similar
demographic and epidemiologic characteristics. However,
studies examining within-country geographical variations in
pharmaceutical prescribing have been scarce (Anis et al., 1996;
Dubois et al., 2002) until recent years (Zhang et al., 2010, 2012;
Donohue et al., 2012) and very few have addressed –and only
partially – the variability in osteoporotic drug consumption
(Rocha et al., 2006; Devold et al., 2010; Crilly et al., 2014; Shah
et al., 2017)..Knowledge of these variations will be essential to
interpret the behavior of healthcare providers and to define
public policies aiming to reduce both the burden of osteoporosis
on patients and unnecessary expenditure on pharmacological
treatment.
The aims of this study are to describe variations in
pharmaceutical utilization and spending on osteoporotic drugs
between Health Areas (HA) in Spain in 2009 and to analyze the
observed variation using small area variation analysis (SAVA)
methods.
MATERIALS AND METHODS
Design
Population-based cross-sectional ecological study of expenditure
and utilization of the five therapeutic groups marketed for
osteoporosis treatment in Spain.
Population
The units of analysis were the 168 HAs of the 13 Spanish
Autonomous Communities (AC) participating in the study
(Andalucia, Aragon, Asturias, Balearic Islands, Canary Islands,
Castilla-Leon, Catalonia, Extremadura, Madrid, Murcia, Navarra,
and the Valencia Region). These HAs, after excluding people not
entitled to pharmaceutical benefits, covered a population of about
39.8 million inhabitants in 2009 (roughly 80% of the Spanish
population at that time), of which 7.2 million were women aged
50 years and over.
Setting
The sNHS – during the study period, previous to the 2012
healthcare reforms on entitlement and copayment – provided
universal healthcare coverage through an extended network
of public or public–private–partnership hospitals and primary
healthcare centers with some features relevant to this study
(Martin-Moreno et al., 2009): health care was free of charge
except for drugs in non-retired people who had a 40% copayment
with a cap on chronic medications; hospital and primary care
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was financed by the regional governments’ budgets, and healtcare
services were organized into HAs, geographically delimited
territories with about 100,000–250,000 people served by one
public hospital and several primary care centers providing
inpatient and outpatient primary and specialized care to the
population in its demarcation. Due to these organizational
characteristics (geographical planning and minimal accessibility
barriers), patients receive most of their care, except highly
specialized care, in the HAs they belong to.
Therapeutic Groups
We selected all drugs (except zoledronate) marketed in
2009 in Spain for osteoporosis treatment categorized into
five Anatomical Therapeutic Chemical (ATC) Classification
groups: M05BA and M05BB (biphosphonate and combinations,
including alendronate, risedronate, ibandronate, etidronate,
and alendronate–colecalciferol), M05BX (strontium ranelate),
G03XC (raloxifene), H05AA (parathyroid hormone and
teriparatide), and H05BA (calcitonin salmon synthetic and
elcatonin). Zoledronate was not included because in Spain it is
administered on an inpatient basis and there is no register of its
use in the outpatient prescription data files.
Data Sources
Utilization and expenditure data were supplied by the Regional
Health Departments from their outpatient drug dispensation
data files, containing information on the pharmacy claims
reimbursed by the regional healthcare services in 2009.
This database includes a description of the drug dispensed
(commercial brand, generic name, strength, size of the package,
retail price), the patient’s coverage (full or 40% copayment),
and the HA in which the prescription was made. The databases
transferred to the research team did not contain any information
on individual patients. Figures about population entitlement
in each HA were obtained from the Health Departments’
entitlement registries.
Main Measure
This was the defined daily dose (DDD) per 1000 inhabitants
and day (DDD/1000/Day) dispensed in each HA according
to the pharmaceutical claims reimbursed by the regional
governments. The DDD is a technical unit of measurement
used in drug utilization studies and assigned by the WHO
Collaborating Center for Drug Statistics Methodology (WHO,
2012), equivalent to the average daily maintenance dose of a
drug in its main indication for adults. The DDD/1000/Day
[(total milligrams consumption in a population aggregated in
DDD × 1000)/(365 days × number of inhabitants in the
population)] is a rough estimate of the number of people per
1000 inhabitants who are consuming a specific drug at any given
moment (point-prevalence). Due to the strong sex-age-related
use of osteoporotic drugs (according to Health Departments non-
published data, men only account for 5% of prescriptions, and for
women only 5% goes to those under 50 years old), we assigned all
prescriptions to the population of women aged 50 years and over
for simplicity and is thus specified as DDD/1000W50/Day from
here on.
Other Measures
(1) The pharmaceutical expenditure on osteoporotic drugs at
retail price per women aged 50 years and over and per year; (2)
the age–copayment Indirect Standardized Drug Utilization Rate
(ISR), obtained by comparing the observed DDD/1000W50/Day
dispensed in each HA with an estimate of the expected
DDD/1000W50/Day in the same HA if its actual population had
the same stratified age and copayment drug utilization registered
in a given reference population (the region of Madrid).
Ethical Aspects
The study, observational in design, uses retrospective
anonymized non-identifiable and non-traceable data transferred
to the research team meeting the requirements of the institutional
providers. It is also in accordance with the CIOMS-WHO
International Ethical Guidelines for Epidemiological Studies
(CIOMS-WHO, 2008) and the Spanish personal data protection
and patients rights’ laws (Ley 15/1999, 1999; Ley 41/2002, 2002),
and did not require Ethics Committee approval.
Analysis
First, we estimated the DDD/1000W50/Day by HA. Second,
expenditure in each therapeutic class was aggregated by
HA and divided by the number of women aged 50 years
and over and by DDD dispensed to obtain the annual
osteoporotic drug cost per woman aged 50 years and older.
Subsequently, Indirect Standardized Drug Utilization Rates
in each HA were estimated by each therapeutic class as
ISR = observed/expected =
∑
i DDDi/
∑
i DUR
R
i Ni, where
DURRi is the drug utilization rate in the ith age–copayment group
in a reference population in which these parameters were known.
We used the available specific rates from the Madrid Region but
recalibrated them to the observed total consumption of the 168
HAs. The indirect method used does not allow the comparison
of one HA with another, but does admit a comparison with
the reference pattern that by construction is equal to the mean
utilization rate of the sNHS for the respective drug. Therefore, an
ISR such as 1.50 for a given HA is interpreted as meaning that this
HA has a 50% higher consumption of the respective drug than the
sNHS average.
A descriptive analysis of drug use (crude and standardized)
and spending per woman was carried out presenting the mean,
median, and the values of the HAs in percentiles (P) 5, 25, 75, and
95. Variability among HAs was analyzed using the usual SAVA
statistics (Ibáñez et al., 2009) but, in order to reduce the influence
of those (few) areas with extreme values, we excluded (unless
otherwise noted) the HAs outside the 5th and 95th percentile
of the corresponding distribution. The statistics used include the
high–low ratio (ratio between HAs in the P5 and P95, also known
as the extremal quotient; EQ5-95), the interquartile range (ratio
between HAs in the P25 and P75; IQR25-75), the coefficient
of variation (CoV5-95), the weighted coefficient of variation
(CoVW5-95), similar to the CoV5-95 but weighted for the size of
the population in each area. The ISRs in each HA and therapeutic
class were also displayed as geographical maps (Supplementary
Figure S1). Finally, Spearman’s correlation was used to analyze
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associations among the ISR of the different therapeutic groups;
a one-way ANOVA random-effects analysis using the ACs as
a factor was used to estimate the proportion of between-HA
variance explained by the membership of the HA to one or
another region. All the analyses were performed using the STATA
13.0 (StataCorp, College Station, TX, United States) statistical
software and R (Free Software Foundation’s GNU General Public
License, Boston, MA, United States).
RESULTS
The average osteoporotic drug consumption in Spain during
2009 was of 116.8 DDD/1000W50/Day, ranging from 78.5 to
158.7 DDD/1000W50/Day between the HAs in the percentiles 5
and 95 (Table 1). Seventy-nine percent of the antiosteoporotics
consumed were bisphosphonates (91.9 DDD/1000W50/Day)
followed by raloxifene (11.2 DDD/1000W50/Day), strontium
ranelate (7.1 DDD/1000W50/Day), calcitonins (5.0
DDD/1000W50/Day), and parathyroid hormones including
teriparatide (1.6 DDD/1000W50/Day). Regarding variability by
therapeutic groups, biphosphonates showed the lowest variation
(twice as high in the HA in the 95th percentile compared to
that in the 5th percentile) while calcitonins and parathyroid
hormones showed the highest variation (10-fold and 18-fold
higher consumption in the HA on the P95 compared to the P5,
respectively). The standardization by age and copayment did not
substantially modify the variability between HAs (Supplementary
Table S1).
Table 2 shows the annual treatment expenditure on
osteoporosis drugs, which was €426.5 million in the 13 regions,
translating into an expenditure of €59.2 for each woman aged
50 years and over, and varying between €38.1 and €83.3 between
HAs in the percentiles 5 and 95 (2.2 times higher in the HA on
the P95 than in the HA on the P5). Biphosphonates, despite
accounting for 78.7% of utilization, only represented 62.9%
of total expenditure on osteoporosis drugs, while parathyroid
hormones with only 1.6% of utilization accounted for 14.9%
of the osteoporosis pharmaceutical spending. Biphosphonates
showed the lowest variation in expenditure (2.1 times higher
between HAs in the 95 and 5 percentiles), followed by raloxifene
(EQ5-95: 4.2) and strontium ranelate (EQ5-95: 5.4), while
calcitonin (EQ5-95: 8.4) and parathyroid hormones (EQ5-95:
15.3) showed the highest variation. As with the utilization rates,
the standardization by age and copayment did not substantially
modify the variability in expenditure per woman between HAs
(Supplementary Table S2).
Spearman correlations between the consumption of the
different therapeutic groups (Table 3) were, in general, moderate
but positive and significant. Three pairs (strontium ranelate
with raloxifene and parathyroid hormones, and raloxifene with
parathyroid hormones) showed coefficients above 0.40. The
ACs explained a substantial part (14%) of the variance in
osteoporosis drug utilization rates (Table 4), with differences
between therapeutic classes, ranging between 15% in the case of
biphosphonates and 54% in the case of parathyroid hormones.
Supplementary Figure S1 shows the geographical distribution
of the indirect standardized rates and the consumption of
each therapeutic group by HAs grouped by ACs is shown in
Supplementary Figure S2.
DISCUSSION
This population-based study assessed variations in
pharmaceutical utilization and spending in osteoporotic drugs
between HAs in Spain. Our results provide evidence of an
important variability between HAs in the use of antiosteoporotic
drugs, with ratios at the 95th percentile more than doubling those
at the 5th percentile for all osteoporosis drugs, and reaching an
18-fold difference for some costly drugs such as parathyroid
hormones. The extent of these differences between territories
was hardly modified by standardizing for age and copayment.
Regarding treatment expenditure, we found that variation in
drug utilization was transferred almost entirely to variation in
expenditure per capita (in this case, per woman aged 50 years and
over) and rates of prescribing explained almost all of the variance
in drug spending. Furthermore, despite finding a moderate
correlation between the use of the different therapeutic groups,
our study also shows that antiosteoporotic drugs are prescribed
TABLE 1 | Defined daily dose per 1000 women aged 50 years and older and day in osteoporosis drugs by Health Areas (HAs) (Spain, 2009).
Biphosph. Strontium R Raloxifene Parathyr. H Calciton. All
Mean 91.93 7.05 11.20 1.63 5.00 116.80
SD 19.09 2.96 5.08 1.28 5.62 24.73
P5 59.85 3.01 3.69 0.24 1.12 78.49
P25 80.27 4.85 7.50 0.69 2.10 99.54
Median 91.59 6.57 10.74 1.32 3.58 116.42
P75 101.10 8.77 14.02 2.19 6.30 130.44
P95 123.28 12.69 20.25 4.22 11.28 158.72
EQ5-95 2.06 4.22 5.49 17.84 10.06 2.02
IQR25-75 1.26 1.81 1.87 3.17 2.99 1.31
CV5-95 0.16 0.33 0.36 0.62 0.60 0.16
CVW5-95 0.15 0.31 0.33 0.56 0.65 0.16
n = 168 HAs. SD, standard deviation; P, percentile; EQ, extremal quotient; IQR, interquartile range; CV, coefficient of variation; CWW, weighted coefficient of variation.
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TABLE 2 | Osteoporosis drugs expenditure per woman aged 50 years and older by HAs (Spain, 2009).
Biphosph. Strontium R Raloxifene Parathyr. H Calciton. All
Mean 37.23 4.52 5.04 8.84 3.58 59.20
SD 7.73 1.90 2.26 6.18 2.61 14.37
P5 24.68 1.94 1.68 1.32 0.97 38.09
P25 32.74 3.12 3.38 4.28 1.89 49.54
Median 36.83 4.21 4.84 7.92 3.03 57.87
P75 41.57 5.65 6.29 11.74 4.53 67.78
P95 52.47 8.17 9.08 20.10 8.13 83.29
EQ5-95 2.13 4.22 5.40 15.27 8.37 2.19
IQR25-75 1.27 1.81 1.86 2.74 2.39 1.37
CV5-95 0.16 0.33 0.36 0.55 0.50 0.19
CVW5-95 0.14 0.30 0.33 0.49 0.51 0.19
SD, standard deviation; P, percentile; EQ, extremal quotient; IQR, interquartile range; CV, coefficient of variation; CWW, weighted coefficient of variation.
TABLE 3 | Spearman correlations between HAs drug utilization rates of osteoporosis drugs (Spain, 2009).
Biphosphonates Strontium ranelate Raloxifene Parathyroid hormones Calcitonins
Biphosphonates
Strontium ranelate 0.28
Raloxifene 0.26 0.46
Parathyroid hormones 0.22 0.41 0.41
Calcitonins 0.35 0.34 0.33 0.25
All the coefficientes were significant at p < 0.05.
TABLE 4 | Variance explained by the Autonomous Community membership of each HA.
Biphosphonates Strontium ranelate Raloxifene Parathyroid hormones Calcitonins All
Indirect standardized drug utilization rates
r2 (ANOVA) 0.19 0.31 0.40 0.55 0.27 0.19
p (ANOVA) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
ICC 0.15 0.28 0.39 0.54 0.24 0.14
Expenditure per woman aged 50 years and older
r2 (ANOVA) 0.19 0.31 0.43 0.44 0.27 0.11
p (ANOVA) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
ICC 0.15 0.28 0.42 0.43 0.23 0.05
Random effects ANOVA one-way analysis (Spain, 2009). ICC, intraclass correlation coefficient.
as complementary treatments rather than as a substitute: HA,
in general, uses all the groups of antiosteoporotics rather than
choosing some groups over others.
Regarding the variability between HA in the use of
antiosteoporotic drugs, we found ratios at the 95th percentile
more than doubling those at the 5th percentile for all
antiosteoporotic drugs altogether, and ranging between a twofold
difference for biphosphonates and an 18-fold difference for some
costly drugs such as parathyroid hormones. These figures are
similar to those reported in previous studies in Portugal (Rocha
et al., 2006) and Norway (Devold et al., 2010) for biphosphonates,
but much higher for other therapeutic groups as compared
with the Portuguese study, which is the only study assesing
differences in several antiosteoporotic drug groups. In such study,
the amplitude of variation ranged from two to three times
across regions for the different antiosteoporotic drugs. Regarding
variability for all antiosteoporotic drugs together, the differences
found in our study were lower than the differences reported
in Canada (Crilly et al., 2014), although the measurements of
variability for the latter study are not comparable to those
of our study. It might be possible that the higher utilization
rates of antiosteporotic drugs evidenced in Spain compared
to other European countries (Richards, 2010) translates into
higher variability in prescription. The extent of differences
in antiosteoporotic drug utilization between territories was
hardly modified by standardizing for age and copayment,
suggesting a limited role for morbidity (age is a good proxy
for the prevalence of osteoporosis) or economic accessibility
as a source of variations between geographical territories. This
finding should be interpreted from the perspective of ecological
studies, avoiding extrapolations to studies on an individual basis
in which both of these factors (age and copayment) predict
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drug consumption accurately. Furthermore, the differential
priorization of non-pharmacological interventions between
regions (such as promotion of changes in diet, weight bearing
exercise, smoking cessation, etc.), together with the variability
in the recommendations among clinical pratice guidelines, may
have influenced the variability in utilization, but it is unlikely that
they do so to the extent of explaining the high variations observed
in our study.
We also found that variation in drug utilization is transferred
almost entirely to variation in expenditure per capita (in this case,
per woman aged 50 years and older) and rates of prescribing
explained almost all of the variance in drug spending. This
finding suggests that the different amounts of medications
prescribed in each territory, rather than their price, are the main
source of variation in osteoporosis drug spending in the sNHS
setting, in contrast to a large US study using Medicare Part D data,
concluding that regional variation in pharmaceutical spending
results largely from differences in the costs of drugs rather than
prescription volume (Donohue et al., 2012). The discrepancy in
findings could be explained by the homogeneity of prices of the
most widely used anti-osteoporotic drugs in Spain, derived from
a price regulation system that includes administrative approval
for the price of brand-name products and a price reference
system for drugs with expired patents. This might not be the case
for other drug groups with a greater variety in prices or with
increased consumption of high-cost groups, or other countries
with different price regulatory systems. Our findings suggest that
the role of prescription volume and price on pharmaceutical
expenditure depends on the drug group and individual context
and should be assessed accordingly, avoiding generalization of the
results from specific settings.
Lastly, and although the correlation between the use of the
different therapeutic groups is moderate, our study also shows
that antiosteoporotic medications were used as complementary
treatments rather than as a substitute: HAs, in general, use all the
groups of antiosteoporotics rather than choosing some groups
over others. This finding does not have a clear clinical rationale
in osteoporosis, where, in contrast to other conditions such
as hypertension, it is exceptional that two different drugs are
used simultaneously in the same patient. This tends to amplify
variations in global spending and has important implications for
the design of practical policies aiming to reduce variability and
pharmaceutical expenditure (Zhang et al., 2011).
The evidence accumulated shows wide geographical variation
in healthcare utilization and spending, which is independent
of patient characteristics and unrelated to the quality of care
or patient outcomes (Bernal-Delgado et al., 2009; Mercuri
and Gafni, 2011). The results of our study on utilization and
spending regarding antiosteoporotic medication are consistent
with limited previous research. These results might be indicators
of inefficient resource use, and at the same time provide an
opportunity for improvement in the quality and value of health
care (Gauld et al., 2011; Mays, 2011; Bernal-Delgado et al.,
2013). In the specific case of antiosteoporotic medications, an
inadequate use (and therefore spending) has been documented
in various settings with prescriptions to women with a low risk of
fracture and a considerable underuse in people with a high risk
of fracture, including those who have already suffered a major
osteoporotic fracture (Sanfélix-Genovés et al., 2013b; Wang et al.,
2013; Yu, 2017), suggesting the existence of considerable room
for improvement in the prevention of osteoporotic fracture.
Our findings are subject to several limitations. First, the
nature of the design (ecological) limits the generalization of the
results from the geographically aggregated population to the
individual basis. Second, the use of data on dispensed drugs may
provide an imprecise estimate of a physician’s prescriptions (as
some prescriptions issued might not be filled). Third, indirect
adjustment for age and copayment may be insufficient to control
for differences in the risk of being treated with antiosteoporotic
drugs. Fourth, we assigned all DDDs consumed to women
aged 50 years and over. Although variations between HAs in
utilization in men or young women could affect our estimates
of variability, we expect this strategy to have a minor impact
on our figures, because the group of women aged 50 years and
over is the population group that consumes the vast majority of
anti-osteoporotic drugs. Fifth, the results presented correspond
to 2009 and might not be extrapolated to the current situation of
antiosteoporotic drug use and spending in Spain (which may have
been affected by several factors, including safety warnings about
bisphosphonates, the expiration of some patents, restrictions of
use and/or withdrawal of some drugs, the incorporation of new
drugs, as well as policies developed in response to the economic
crisis or the impoverishment of the population itself). A very
recent study (Martín-Merino et al., 2017) shows trends in the use
of antiosteoporotics until 2013, reporting an important decrease
during the economic crisis (as it happened with medications
aimed to treat other diseases). Also, as some patents have expired
from 2009 and new drugs have entered into the market, it is likely
that the expenditure in antiosteoporotic drugs has changed in the
current context.
Although the level and patterns of use and expenditure might
have changed, to our knowledge no other study has assessed the
variability in anti-osteoporotic drug prescribing and spending in
a comprehensive manner to date, across the Spanish territory, nor
in other settings. Therefore, we are presenting novel results, with
the most recent information available at the Health Area level
regarding this relevant topic.
CONCLUSION
In summary, this study highlights a marked geographical
variation in the prescription of antiosteoporotic treatments in a
setting with universal healthcare coverage, the variation being
more pronounced in the case of costly (but low-prescription)
drugs such as parathyroid hormones. The differences in rates
of prescribing explained almost all of the variance in drug
spending, suggesting that the difference in prescription volume
between territories, and not the price of the drugs, is the
main source of variation in this setting. Our study also shows
that antiosteoporotic drugs are prescribed as complementary
treatments rather than as a substitute, overall: HAs prescribe
all the groups of antiosteoporotics rather than choosing
some groups over others. Our findings are useful to identify
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inconsistencies in the clinical management of a major health
problem for older people (especially women) as is osteoporosis,
and the prevention of its more severe clinical manifestation:
hip fracture. Data on geographical variation of prescription can
help guide policy proposals for targeting areas with inadequate
antiosteoporotic drug use.
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